🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 21 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/11/2022 364,00 369,20 356,30 362,00 -0,82% 3,54% 49.081
07/11/2022 367,90 368,20 358,10 365,00 -1,83% 2,75% 49.521
04/11/2022 387,30 388,00 369,00 371,80 -3,53% 4,91% 74.346
03/11/2022 378,00 387,20 376,70 385,40 +1,18% 2,78% 43.919
02/11/2022 387,20 392,30 377,30 380,90 -3,15% 3,87% 67.331
01/11/2022 394,10 400,70 390,20 393,30 -0,38% 2,66% 63.004
31/10/2022 386,20 395,70 380,40 394,80 +2,60% 3,96% 68.599
28/10/2022 366,00 385,00 361,40 384,80 +7,37% 6,45% 98.452
27/10/2022 388,00 405,50 357,00 358,40 -7,63% 12,50% 117.240
26/10/2022 390,50 393,70 385,90 388,00 -0,49% 2,00% 52.271
25/10/2022 385,00 390,50 382,60 389,90 +2,55% 2,05% 49.602
24/10/2022 375,30 381,40 374,20 380,20 +0,40% 1,92% 67.869
21/10/2022 369,40 378,70 367,30 378,70 +3,58% 3,09% 73.391
20/10/2022 370,10 370,50 350,80 365,60 -2,27% 5,32% 65.590
19/10/2022 380,80 383,00 372,30 374,10 -0,93% 2,81% 46.742
18/10/2022 370,80 379,80 369,30 377,60 +1,64% 2,83% 48.716
17/10/2022 362,00 371,90 360,00 371,50 +2,57% 3,29% 44.785
14/10/2022 361,60 365,70 358,50 362,20 +2,11% 1,99% 39.105
13/10/2022 353,60 356,70 347,50 354,70 +0,48% 2,60% 37.781
12/10/2022 357,60 360,90 350,30 353,00 -2,43% 2,96% 48.395
11/10/2022 356,80 363,40 350,60 361,80 +1,40% 3,59% 40.185
10/10/2022 361,40 362,90 356,00 356,80 -1,87% 1,91% 46.677
07/10/2022 378,30 378,60 363,40 363,60 -4,57% 4,02% 53.314
06/10/2022 379,20 384,90 376,70 381,00 +0,58% 2,16% 48.668
05/10/2022 368,00 379,00 366,40 378,80 +3,13% 3,42% 41.197
04/10/2022 362,00 374,30 360,90 367,30 +1,60% 3,70% 75.544
03/10/2022 363,70 367,60 356,50 361,50 -1,90% 3,05% 45.527
30/09/2022 365,60 370,20 363,10 368,50 +0,68% 1,94% 70.493
29/09/2022 368,20 371,40 360,50 366,00 -0,19% 2,96% 56.566
28/09/2022 366,90 368,00 357,80 366,70 -0,70% 2,78% 58.106